EGFR and non-small cell lung carcinoma: Cetuximab has demonstrated antitumor activity in a variety of models, including non–small cell lung cancer (NSCLC) models expressing wild-type and mutant EGFR (6), and has been reported to induce apoptosis in NSCLC model H1975 (7).